Antibody Drug Conjugates in Metastatic Breast Cancer | Sramila Aithal, MD | ESMO22 Pennsylvania

ASCO22 Metastatic Breast Cancer Updates | Sramila Aithal, MD | US OncologyПодробнее

Antibody-drug conjugates for the treatment of breast cancerПодробнее

Advances in antibody-drug conjugates for breast cancer at ESMO 2022Подробнее

Antibody Drug Conjugates in Metastatic Breast Cancer | Anthony Elias, MD | ESMO22 ColoradoПодробнее

New Classifications and Staging in Breast Cancer | Manisha Bahl, MD | ESMO22 PennsylvaniaПодробнее

Emerging Antibody-Drug Conjugates in Breast Cancer: An Expert Analysis of Promising TherapiesПодробнее

How Are Antibody Drug Conjugates Used to Treat Breast Cancer? All You Need to KnowПодробнее

Novel antibody-drug conjugates (ADCs) technologies for management of mBCПодробнее

Dr. Sramila Aithal on the EMILIA Trial Studying T-DM1 in Metastatic Breast CancerПодробнее

Emergence of antibody-drug conjugates in metastatic breast cancer: 2022 ESMO FloridaПодробнее

Dr. Michelle Fanale on the Potential of Antibody-Drug ConjugatesПодробнее

Antibody Drug Conjugates in Breast and GYN CancerПодробнее

Study of DS-8201a in HER2-Low, Unresectable and/or Metastatic Breast CancerПодробнее

Global Challenges in Genomic Profiling & Precision Oncology | Shayma Kazmi, MD, RPh | ESMO22 PAПодробнее

HER2+ Breast Cancer: Evolution of Antibody-Drug ConjugatesПодробнее

Dr. Hart on Antibody-Drug Conjugates in HER2+ Breast CancerПодробнее

Dr. Sramila Aithal Describes the HERceptin Adjuvant (HERA) Trial for HER2-Positive Breast CancerПодробнее

Where are we in sequencing ADCs in HR+ breast cancer?Подробнее